Orally active, potent aromatase (CYP19) inhibitor (IC50
values are 0.4 and 0.12 nM at rat ovary and human placenta cells respectively) that only weakly inhibits the synthesis of other steroid hormones. Reduces plasma estrogen levels into ranges induced by ovariectomy and inhibits testosterone-induced breast cancer cell growth in vitro
= 0.13 nM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
(Sold with the permission of Astellas Pharma Inc.)
Studies on aromatase inhibitors I. Synthesis and biological evaulation of 4-amino-4H-1,2,4-triaole derivatives.
Okada et al.
The potent and selective inhibiton of estrogen production by non-steroidal aromatase inhibitor, YM511.
Kudoh et al.
J.Steroid Biochem.Molec.Biol., 1995;54:265